Patient's own immune cells plus drug tested against tough melanoma
NCT ID NCT05176470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether giving a patient's own lab-grown tumor-fighting immune cells (Lifileucel) together with the immunotherapy drug pembrolizumab can safely shrink advanced melanoma. Only 2 people with stage IIIB-D or IV melanoma took part. The goal is to see if this combination is feasible and safe before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lifileucel (tumor-infiltrating lymphocytes) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a way to shrink advanced melanoma tumors before surgery using a patient's own immune cells combined with an immunotherapy drug.
What could go wrong
This is a very early Phase 1 trial with only 2 participants, so results may not apply to others. The treatment involves strong chemotherapy beforehand, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States